Who are we? MS Ventures is the global corporate VC arm of Merck - - PowerPoint PPT Presentation

▶
who are we
SMART_READER_LITE
LIVE PREVIEW

Who are we? MS Ventures is the global corporate VC arm of Merck - - PowerPoint PPT Presentation

Dec 29, 2023 547 likes •682 views

Who are we? MS Ventures is the global corporate VC arm of Merck Serono MS Ventures strategic fund: 110m MS Ventures Entrepreneur Partnership Program: 30m Israel BioIncubator Fund: 10m 1 Decision making process 2 Project

slide-1
SLIDE 1

Who are we?

MS Ventures is the global corporate VC arm of Merck Serono

1

MS Ventures strategic fund: €110m Israel BioIncubator Fund: €10m Entrepreneur Partnership Program: €30m

MS Ventures

slide-2
SLIDE 2

Decision making process

2

slide-3
SLIDE 3

3

”Project scoring”-table

(Medical) need

 Yes  No

Proprietary

 Yes  No

Differentiation

 Yes  No

People

Personality Track Record Incentives

Potential

Market size Competition Pricing / margin

Timing

Time to market Penetration rate Exclusivity

Risk

Development Regulatory Market

Cost structure

Development Inflection points Commercial

slide-4
SLIDE 4

Where to find us

www.ms-ventures.com

4

slide-5
SLIDE 5

Merck Inhouse Consulting

Backup slides

slide-6
SLIDE 6

P A R E N T

  • Leverage RD expertise for “wet due diligence”
  • Nurture assets through active R&D involvement
  • Offer access to manufacturing, screening capabilities etc. at

cost, at risk and/or in exchange for equity

  • Front-row seat, early due diligence, preferred relationship
  • Foster corporate entrepreneurship within Merck
  • Catalyze exchange and creation of novel of ideas

MS Ventures investment strategy

Pharma focus on products, allowing biotech creativity and speed

P O R T F O L I O

  • Strategic assets
  • Critical path to commercial relevance
  • Emphasis on business development
  • Tactics follow asset strategy
  • Top tier syndicates
  • A –Teams; Management, Board & SAB
  • Hands on board support
  • Interim C roles where needed

6

slide-7
SLIDE 7

7

MS Ventures

Global Team

Roel Bulthuis Managing Director roel.bulthuis@ms- ventures.com AMSTERDAM Nilesh Kumar Director nilesh.kumar@ms- ventures.com BOSTON Jasper Bos Director jasper.bos@ms- ventures.com GENEVA Simone Botti Head of Israel Incubator Fund simone.botti@ms- ventures.com TEL AVIV Hakan Goker Director hakan.goker@ms- ventures.com AMSTERDAM Edward Kliphuis Associate edward.kliphuis@ms- ventures.com AMSTERDAM Laila Gharzai Analyst laila.gharzai@ms- ventures.com AMSTERDAM Alicia Irurzun-Lafitte Associate alicia.irurzun-lafitte @ms-ventures.com BOSTON

slide-8
SLIDE 8

8

MS Ventures at a glance

Investing in Innovation

MS Ventures strategic fund: €110m Israel BioIncubator Fund: €10m Entrepreneur Partnership Program: €30m

MS Ventures

slide-9
SLIDE 9

9

Top 20 early stage VCs 2012 - 20131

# Investor Financings Total ($m) Average ($m) 1 MS Ventures* 11 $71.2 $6.5 2 OrbiMed Advisors 10 $158.5 $15.9 3 Novartis* 9 $188.0 $20.9 4 Novo A/S* 9 $157.9 $17.6 5 Third Rock Ventures 8 $274.2 $34.3 6 Polaris Venture part. 7 $114.9 $16.4 7 MPM Capital 7 $136.0 $19.4 8 5AM Ventures 7 $195.0 $27.9 9 SR One* 7 $114.0 $16.3 10 Atlas Venture 6 $44.2 $7.4 11 Flagship Ventures 6 $173.5 $28.9 12 Sofinnova Ventures 5 $190.5 $38.1 13 New Enterprise 5 $135.9 $27.2 14 Canaan Partners 5 $113.5 $22.7 15 Fidelity 5 $80.4 $16.1 16 Pfizer Inc.* 5 $128.4 $25.7 17 SV Life Sciences 5 $86.7 $17.3 18 Hatteras Venture 5 $57.0 $11.4 19 Abingworth mgmt 4 $119.3 $29.8 20 Connecticut Innov. 4 $8.5 $2.1

Strategic investors

MS Ventures is an active early stage investor

Hands-on approach to the building of companies

1 Number of Seed- and Series A investments completed in 2012 and 2013. Source: BioCentury BCIQ 2 Source: PwC Moneytree 2012; NVCA; numbers are for all Life Sciences deals, inc. diagnostics and agro

  • MSV supports portfolio companies

directly and through continued interaction with relevant Merck Serono experts

  • Takes an active role in the

refinancing processes of our companies

  • Financing plans are structured

around the critical path towards proving commercial relevance

  • Aims to define relevant datapoints
  • n that path as a basis for

refinancing decisions

  • Places significant emphasis on the

quality of our management teams, Boards and Scientific Advisory Boards and dedicate a significant amount of our time to finding the best candidates for these positions

slide-10
SLIDE 10

10

  • Unique science
  • Proprietary technology
  • Differentiation
  • Commercial relevance
  • Medical need
  • Risk
  • People
  • Pricing model

Focus on differentiation, need and people

MSV financing checklist

slide-11
SLIDE 11

11

Show me that…my product works better

  • Really?
  • How?
  • Better than what?
  • Better efficacy?
  • Better safety?
  • How can I test that?
  • When can I test that?
  • Will I be rewarded for it?
slide-12
SLIDE 12

12

Move to trash

  • „This mechanism is unique, biologically“
  • „We see no side effects at all“
  • „We can significantly reduce the risks of

drug development“

  • „We‘re the only ones in the world, there is

no competion“

  • „Lowering COGS of mAbs in the ONC

field significantly“

  • „My professor has been working on this

for 20 years“

  • „We have a highly specific siRNA, just

need to solve delivery“